

Factors Contributing to Local Recurrence after Conservative Breast Surgery for Early Breast Cancer

Thesis

Submitted for partial fulfillment of the MD degree in General Surgery

By

Mohamed Gamal Elsayed Mostafa Qassem

M.B.B.Ch, M.Sc.

Faculty of Medicine, Ain Shams University

Under supervision of

Prof. Dr. Ashraf Abdel Moghny Mostafa

Professor of General Surgery

Faculty of Medicine, Ain Shams University

Prof. Dr. Mohamed Mohamed El-Bassiouny

Professor of Clinical Oncology & Nuclear Medicine

Faculty of Medicine, Ain Shams University

Prof. Dr. Mohamed El-Sayed El-Shinawi

Professor of General Surgery

Faculty of Medicine, Ain Shams University


Prof. Dr. Youhanna Shohdy Shafik

Assistant Professor of General Surgery

Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University*

2016



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
قَالُوا سُبْحَانَكَ
لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ
الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة

الآية (٣٢)



Acknowledgement

My greatest gratitude is to **ALLAH** whose guidance and support were the main motives behind accomplishing this work.

I would like to express my special thanks to **Prof. Dr. Ashraf Abdel Moghny Mostafa**, Professor of General Surgery, Faculty of Medicine, Ain Shams University for his scholarly advice and fatherly assistance during all the phases of this work.

I am also expressing my appreciation to **Prof. Dr. Mohamed Mohamed El-Bassiouny**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University for his great support, and kind guidance throughout this work.

Many thanks to **Prof. Dr. Mohamed El-Sayed El-Shinawi**, Professor of General Surgery, Faculty of Medicine, Ain Shams University for his unlimited assistance throughout my career.

Many thanks to **Prof. Dr. Youhanna Shohdy Shafik**, Assistant Professor of General Surgery, Faculty of Medicine, Ain Shams University for his kind guidance throughout this work.

Sincere thanks are also extended to all my **senior staff and colleagues** in the general surgery department (6A subunit) for their valuable remarks and faithful cooperation.

I would like to express my deep appreciation and gratitude to my **family** for their generous and infinite help and continuous guidance throughout my whole life. I ask **ALLAH** to bless them keeping them happy and safe ever.

Last but not least, I would like to express my endless gratitude to my dear **patients** for their kind cooperation in accomplishing my work, wishing them a good health.

Mohamed Gamal

Dedication

*To my **parents** who devoted their life for us
and always push me forward.*

*To my kids **Yaseen** and **Sondos** who provide
me with the power and motivation in my
life.*

List of Contents

Title	Page No.
Introduction.....	1
Aim of the Study.....	3
Review of Literature	4
Cytogenetics and Pathology of Breast Cancer	4
Diagnosis of Early Breast Cancer (EBC).....	16
Treatment Modalities of Early Breast Cancer	32
Management of Local Recurrence after BCS.....	44
○ Risk Factors of Local Recurrence after BCS	
○ Diagnosis of Local Recurrence after BCS	
○ Treatment Options of Local Recurrence after BCS	
Patients and Methods.....	62
Results.....	70
Discussion	84
Summary and Conclusion.....	93
References.....	98
Arabic Summary	

List of Abbreviations

ALND	Axillary lymph node biopsy
BCS.....	Breast conserving surgery
BCT	Breast conserving therapy
BIRADS.....	Breast Reporting and Data System
CC.....	Craniocaudal
CNB.....	Core needle biopsy
DCIS	Ductal carcinoma in situ
DFS.....	Disuse free survival
DNA.....	Deoxy Necleic acid
EBCTCG	Early Breast Cancer Trialists' Collaborative Group
ECD	Extracellular domain
EORTC	European Organization for Research and Treatment of Cancer
ER	Estrogen receptor
FDA	Food and drug administration
FDG	Flurodeoxy glucose
FNA	Fine needle aspiration
GEP.....	Gene expression profiling
HER-2.....	Human epidermal growth factor receptor-2
IBTR	Unilateral breast tumor recurrence
IDC	Invasive ductal carcinoma
IHC	Immunohistochemistry
ILC.....	Invasive lobular carcinoma

IORI	Intra operative radio therapy
LCIS.....	Lobular carcinoma in situ
LR	Local recurrence
LRR	Local recurrence rater
MDT	Multidisciplinary team
MLO	Mediolateral oblique
MRI.....	Magnetic resonance imaging
MRM	Modified radical mastectomy
NST.....	No special type
PBI	Partial breast irradiation
PET	Positron emission tomography
PR	Progesterone receptor
RT	Radiotherapy
VAB.....	Vacuum assisted biopsy

List of Tables

Table No.	Title	Page No.
Table (1):	American joint committee on cancer staging system for patient with cancer breast (AJCC)	14
Table (2):	BI-RADS report final assessment categories.....	19
Table (3):	Risk factors for axillary recurrence.	48
Table (4):	Description of personal data	72
Table (5):	Study population characteristics.....	73
Table (6):	Relation between mean age and local recurrence	74
Table (7):	Relation between family history and local recurrence	75
Table (8):	Relation between tumour size and local recurrence....	75
Table (9):	Relation between LN status and local recurrence	76
Table (10):	Relation between tumour In-Situ Component and local recurrence	76
Table (11):	Relation between safety margin and local recurrence	77
Table (12):	Relation between histologic type and local recurrence	78
Table (13):	Relation between histologic grade and local recurrence	79
Table (14):	Relation between ER status and local recurrence	80
Table (15):	Relation between PR status and local recurrence	81
Table (16):	Relation between HER status and local recurrence ..	82
Table (17):	Relation between tumour Ki 67 and local recurrence	83

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Ductal carcinoma in-situ (solid-type). Histologic section. Hematoxylin and Eosin stain	10
Fig. (2):	Invasive Duct Carcinoma	12
Fig. (3):	Needle core biopsy of a breast lesion.....	27
Fig. (4):	Management of loco-regional recurrence.....	57
Fig. (5):	One of our patients shows a mass on examination. The skin overlying is marked.....	63
Fig. (6):	A mammogram shows suspicious mass with speculated margin.....	64
Fig. (8):	family history among study population.....	72
Fig. (9):	Incidence of local recurrence.	74
Fig. (10):	Local Recurrence regarding safety margins.	77
Fig. (11):	Local Recurrence among histological types.....	78
Fig. (12):	Local Recurrence among histological grades.	79
Fig. (13):	Local Recurrence among ER positive and negative cases.....	80
Fig. (14):	Local Recurrence among PR positive and negative cases	81
Fig. (15):	Local Recurrence among HER positive and negative cases.....	82

Introduction

Breast conservative surgery has been a recognized method of treatment of early breast cancer. This method includes quadrantectomy or wide local excision combined with ipsilateral axillary nodal dissection followed by radiotherapy. Modified radical mastectomy continues to be appropriate for some patients, but breast conservation therapy is now regarded as the optimal treatment for most of the patients (*Luini et al., 2009*).

Several randomized trials with very long follow-ups have established that breast-conserving therapy and mastectomy share equivalent outcomes in terms of overall survivals. Breast-conserving surgery followed by a course of postoperative radiotherapy is considered to be the current standard of care for patient with early operable breast cancer (*Alain et al., 2007*).

The technique of breast conservative surgery has gained enormous popularity over the last two decades. The aim of such treatment is to eradicate the breast cancer while preserving the maximum amount of the breast tissue without increasing risk of local recurrence (*Fisher et al., 2005*).

Contraindications to breast conservative surgery includes two or more primary tumors located in different quadrants of the breast associated diffuse micro calcifications which appear malignant, or a woman with previous breast irradiation. Breast irradiation cannot be given during pregnancy, but it may be possible to perform breast conserving surgery in the third trimester and irradiation can be administered after delivery (*Silverstein et al., 2006*).

The greatest concern in breast-conserving surgery remains the local recurrence, which can provoke serious anxiety to the patient (*E. Botteri et al., 2010*).

The risk factors for local recurrence of breast cancer which have been reported include large tumor size, multifocality, axillary lymph node involvement, young age, high nuclear grade, extent of the intraductal component and positive surgical margin status. Among these, the most important factor involved in local recurrence is positive surgical margin status (*Luini et al., 2009*).

An important treatment related risk factor for local recurrence is the adequacy of surgical excision. This is demonstrated by the fact that most recurrence after breast conservative surgery occurs at the same side of and are clonally related to their primary lesions (*Bijker et al., 2006*).

Clinical history, physical examination and breast imaging are the most effective means of follow up. Physical examination should be performed every three to six months for the first three years following surgery, and every six months in the years four and five. After five years, annual physical examination provides adequate follow up. Patients at exceptionally high risk of recurrence or development of a second primary tumor should be watched more closely. Magnetic Resonance (MR) mammography is important for the early recognition of recurrence and should then be done at least annually (*Veronesi et al., 2006*).

In our study, we will report our experience with 137 patients with early breast cancer who are candidates for conservative breast surgery to detect factors contributing to local recurrence.

Aim of the Study

Our study aims to highlight factors that may contribute to local recurrence after conservative breast surgery for early breast cancer.

Cytogenetics and Pathology **of Breast Cancer**

Carcinogenesis of breast carcinoma:-

Carcinogenesis is a multistep process characterized by genetic alternations that influence key cellular pathways involved in growth and development (**Cynthia et al., 2004**).

As regards breast cancer, malignancy results from step wise genetic alternations of normal host cells , and , possibly from other non genetic (or epigenetic) changes in the behavior of not only malignant cells but also host cells that interact with the tumor , such as immune , vascular, and stromal cell (**Balmain et al. ,2003**).

(A) Oncogenes :-

Oncogenes refer to genes whose activation can contribute to the development of cancer. Activation can occur through gene amplification such that more of protein encoded by the gene is present; hence, its function is enhanced. An example of such a mode of oncogene activation is that of HER-2 (Human Epidermal Growth Factor Receptor-2), which is seen in about 20% of primary breast cancer cases (**Downward, 2003**).

Amplification and overexpression of these oncogenes and oncogene products are the major mechanisms through which these genes participate in carcinogenesis. Amplification may involve short chromosomal regions to chromosomal arms, involving hundreds of genes, to entire chromosomes. The following are descriptions of those oncogenes and proto-oncogenes (pre-activation) as well as their role in breast cancer carcinogenesis (**Cynthia et al., 2004**).

(1) The HER-2 oncogenes:

The HER-2 (also known as The HER-2/neu or c-erbB-2) gene is located on chromosome 17q and encodes a 185-KDa transmembrane tyrosine kinase growth factor receptor (**Yarden and Sliwkowski, 2001**).

Numerous studies have strongly suggested its association with higher recurrence risk in early stage breast cancer and, to a lesser extent increased resistance to hormonal therapy (**Ross et al., 2003**).

(2) Myc oncogene:

C-myc oncogene has been localized to chromosome 8q24 and encodes a nuclear phosphoprotein that acts as a transcriptional regulator involved in cellular proliferation, differentiation and apoptosis. It is amplified and overexpressed in 15%-20% of breast cancer, and in some series, has been associated with worse prognosis or more aggressive clinical features (**Nass and Dickson, 1997**).

While many agree that overexpression of this gene is clearly associated with breast cancer, still a controversy about whether or not aberrant Myc expression alone is sufficient for breast carcinogenesis. On the other hand, Myc plays a role in hormone responsiveness and chemotherapy resistance to the breast tumors (**Carroll et al., 2002**).

(B) tumor suppressor genes:

Tumor suppressor genes are usually negative regulators of growth or other functions that may affect invasive and metastatic potential, such as cell adhesion and regulation of protease activity. Although inherited abnormalities account for a minority of breast cancer cases, germline mutations occur in tumor suppressor genes.

These some genes can harbor sporadic acquired somatic mutations. In both cases, the tumor typically contains a mutation in one allele and a deletion of the remaining allele in keeping with the long standing "two-hit" hypothesis formulated by Alfred Knudson in reference to retinoblastoma, which states that both gene alleles must be lost to unmask the malignant phenotype (**Knudson, 2000**).

(1) The retinoblastoma (pRb) gene:

It was the first tumor suppressor gene to be discovered. In breast cancer, mutation or loss of pRb gene is present in up to 30% of cases of breast cancer (**Andersen et al., 1992**).

(2) p16 gene:

One of the most commonly inactivated tumor suppressor genes in human cancer is p16 gene. P16 gene is a cyclin-dependant kinase inhibitor that regulates progression through G1 phase of the cell cycle by binding and inhibiting cyclin-dependent kinases 4 and 6, P16 alleles can be inactivated during neoplastic progression by multiple mechanisms, including deletion and mutation (**Deshmane and Fentiman, 2002**).

(3) p53 gene:-

Mutation of P53 is estimated to occur in up to half of all human cancers and in approximately 20%-30% of breast cancers (**Hollstein et al., 1991**).

Li-Fraumeni syndrome, a rare autosomal dominant familial predisposition to a Variety of malignancies including breast cancer, sarcomas, leukemia, and brain tumours as early as the second and third decades of life, has been shown to result from germline alternations of p53, and multiple mutation sites have been reported. The risk of cancer of these patients has been